Valuation: Geron Corporation

Market Cap 612M 549M 502M 458M 863M 57.54B 890M 6.05B 2.41B 30.7B 2.3B 2.25B 96.92B P/E 2026 *
-22.5x
P/E 2027 * 15x
Enterprise Value 612M 549M 502M 458M 863M 57.54B 890M 6.05B 2.41B 30.7B 2.3B 2.25B 96.92B EV / Sales 2026 *
2.6x
EV / Sales 2027 * 1.79x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+4.18%
1 week+4.61%
Current month+10.67%
1 month-18.20%
3 months-39.28%
6 months-40.01%
Current year-25.02%
1 week 0.88
Extreme 0.8847
1.09
1 month 0.84
Extreme 0.84
1.26
Current year 0.84
Extreme 0.84
2.01
1 year 0.84
Extreme 0.84
2.01
3 years 0.84
Extreme 0.84
5.34
5 years 0.84
Extreme 0.84
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 55 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Free

Director

6,351 0.0010%
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+4.18%+4.61%-9.19%-50.01% 612M
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.42%+12.77%+75.21% 57.24B
-1.34%+3.53%+23.22%+101.58% 57.62B
+2.62%-1.17%+29.37%+37.84% 43.65B
+5.09%+9.53%+26.62%+121.44% 44.03B
+8.24%+1.06%+224.03%+767.69% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-6.89%+91.79%+74.60% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.70%+3.16%+51.74%+125.82% 40.5B
Weighted average by Cap. +0.06%+2.45%+53.85%+137.77%

Financials

2026 *2027 *
Net sales 235M 211M 193M 176M 332M 22.12B 342M 2.33B 927M 11.8B 883M 864M 37.27B 341M 306M 280M 255M 481M 32.06B 496M 3.37B 1.34B 17.11B 1.28B 1.25B 54B
Net income -25.41M -22.79M -20.83M -19.01M -35.82M -2.39B -36.95M -251M -100M -1.27B -95.37M -93.33M -4.02B 37.75M 33.86M 30.94M 28.24M 53.21M 3.55B 54.89M 373M 149M 1.89B 142M 139M 5.98B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
06/11/26 US$0.9898 +4.18% 13,563,069
05/11/26 US$0.9501 -12.03% 25,833,003
04/11/26 US$1.080 +16.13% 26,877,526
03/11/26 US$0.9300 +0.10% 58,834,805
02/11/26 US$0.9291 +3.88% 13,797,240
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.9501USD
Average target price
3.625USD
Spread / Average Target
+281.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock